Theravance Biopharma (TBPH) Cash from Financing Activities (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Cash from Financing Activities data on file, last reported at -$5.6 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 553.04% year-over-year to -$5.6 million in Q1 2026; TTM through Mar 2026 was -$8.0 million, a 387.52% decrease from a year earlier, with the FY2025 full-year figure at -$3.2 million, down 30.08% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at -$5.6 million, down from -$1.5 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for TBPH reached as high as $140000.0 in Q2 2022 and fell as low as -$722.0 million in Q3 2022.
• Historically, Cash from Financing Activities has averaged -$55.8 million across 5 years, with a median of -$1.5 million in 2025.
• Across the five-year window, Cash from Financing Activities sank 57728.57% in 2023 and soared 99.95% in 2024, its largest moves.
• Year by year, Cash from Financing Activities stood at -$15.3 million in 2022, then sank by 100.28% to -$30.6 million in 2023, then soared by 98.81% to -$365000.0 in 2024, then tumbled by 308.49% to -$1.5 million in 2025, then slumped by 274.04% to -$5.6 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$5.6 million in Q1 2026, -$1.5 million in Q4 2025, and -$400000.0 in Q3 2025.